Authors: Jiang H, Che J.
DOI: 10.3389/fphar.2025.1698727
Abstract Summary
HS630, a biosimilar candidate for trastuzumab emtansine (T-DM1/Kadcyla®), demonstrates comparable binding affinity to HER2 receptors and similar pharmacokinetic profiles in preclinical studies. Testing in tumor-bearing mice and cynomolgus monkeys showed matching drug concentrations and distribution patterns, with no immunogenicity concerns detected. These findings support HS630’s biosimilarity to Kadcyla® and provide critical data for regulatory approval.
Why Brain? 🧠
HS630 demonstrates comparable binding affinity, pharmacokinetics, and immunogenicity to trastuzumab emtansine in preclinical studies, supporting its development as a biosimilar for HER2-positive cancer treatment.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
